Literature DB >> 22089892

Is it worth offering cardiovascular disease prevention to the elderly?

Helmut Gohlke1.   

Abstract

The question whether prevention in the elderly or in the old is still worthwhile arises frequently in clinical practice. The life expectancy (LE) of elderly persons is often underestimated and ranges for a 65-year-old European person from 17 to 23 years and for an 80-year-old from 8 and 11 years. In the elderly patients with cardiovascular disease, preventive measures are of great benefit. Smoking cessation results in substantial gains in LE and is more effective than most other interventions. Lipid lowering with statins is cost effective and the intensity of low-density lipoprotein cholesterol lowering correlates with the risk reduction of cardiac events and stroke without increasing the risk of cancer. A quality-adjusted life year costs US $ 18,800, less than the costs of a nursing home for 1 year. Exercise training decreases cardiovascular events and improves quality of life. The benefits of the Mediterranean diet are based on a small randomized trial, which is supplemented by a large observational database. A reduction in all-cause, cardiovascular disease, and cancer mortality is highly likely. Blood pressure lowering reduces stroke and all-cause mortality above the age of 80; however, the target blood pressure should be around 150/80 mmHg or slightly lower. Annual vaccination against influenza is one of the most cost-effective methods to prolong life and should not be forgotten in patients with cardiovascular disease above the age of 65. Thus a number of options are available to add quality-adjusted life years in the elderly by adhering to the general guidelines for cardiovascular prevention.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089892     DOI: 10.1177/1741826711430384

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  5 in total

1.  Evaluation of varenicline usage on ventricular repolarization after smoking cessation.

Authors:  Duygu İlke Yıldırım; Mert İlker Hayıroğlu; Neriman Ünal; Mehmet Ali Eryılmaz
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-11-12       Impact factor: 1.468

2.  WHO guidelines for a healthy diet and mortality from cardiovascular disease in European and American elderly: the CHANCES project.

Authors:  Nicole Jankovic; Anouk Geelen; Martinette T Streppel; Lisette Cpgm de Groot; Jessica C Kiefte-de Jong; Philippos Orfanos; Christina Bamia; Antonia Trichopoulou; Paolo Boffetta; Martin Bobak; Hynek Pikhart; Frank Kee; Mark G O'Doherty; Genevieve Buckland; Jayne Woodside; Oscar H Franco; M Arfan Ikram; Ellen A Struijk; Andrzej Pajak; Sofia Malyutina; Růžena Kubinova; Maria Wennberg; Yikyung Park; H Bas Bueno-de-Mesquita; Ellen Kampman; Edith J Feskens
Journal:  Am J Clin Nutr       Date:  2015-09-09       Impact factor: 7.045

3.  A prospective study of risk factors for cardiovascular events among the elderly.

Authors:  Marcos Aparecido Sarria Cabrera; Selma Maffei de Andrade; Arthur Eumann Mesas
Journal:  Clin Interv Aging       Date:  2012-11-01       Impact factor: 4.458

Review 4.  Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence.

Authors:  Michael V Burke; J Taylor Hays; Jon O Ebbert
Journal:  Patient Prefer Adherence       Date:  2016-04-01       Impact factor: 2.711

5.  Smoking cessation interventions following acute coronary syndrome: a missed opportunity?

Authors:  Rachael Boggon; Adam Timmis; Harry Hemingway; Sunil Raju; Franco Mondello Malvestiti; Tjeerd P Van Staa
Journal:  Eur J Prev Cardiol       Date:  2012-09-05       Impact factor: 7.804

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.